Physician profile
Angelo E Ayar
NPI 1386888592
$15,396.03
in general payments reported to CMS, 2019-2025
29 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $555 · 2021: $1,093 · 2022: $896 · 2023: $6,211 · 2024: $4,184 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $4,686 · Education: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $4,685.81 |
| Education | $410.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,499.30 | 2019-2025 | Skyrizi, Botox |
| Janssen Biotech, INC. | $1,442.34 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $488.77 | 2019-2023 | |
| Pfizer INC. | $464.69 | 2019-2025 | |
| Incyte Corporation | $426.39 | 2022-2025 | Opzelura |
| Genzyme Corporation | $376.54 | 2020-2025 | |
| Ucb, INC. | $359.01 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $348.24 | 2021-2025 | Dupixent |
| Organogenesis INC. | $317.13 | 2021-2025 | Puraply, Via Matrix |
| Amgen INC. | $261.90 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $239.78 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $214.72 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $174.50 | 2020-2021 | |
| Strata Skin Sciences, INC. | $172.64 | 2019-2024 | Xtrac |
| Novartis Pharmaceuticals Corporation | $111.63 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $101.07 | 2023 | Vtama |
| Allergan, INC. | $81.29 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $57.86 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $42.41 | 2025 | |
| Biofrontera INC. | $36.66 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Revance Therapeutics, INC. | $33.98 | 2025 | Daxxify |
| Organon LLC | $25.24 | 2025 | Vtama |
| Merz North America, INC. | $21.40 | 2022 | |
| Celgene Corporation | $17.96 | 2019 | |
| Epi Health, LLC | $17.84 | 2019 | |
| Merck Sharp & Dohme LLC | $16.91 | 2019 | |
| Dusa Pharmaceuticals, INC. | $16.50 | 2019 | |
| Almirall LLC | $15.72 | 2021 | |
| Leo Pharma INC. | $13.61 | 2025 | Anzupgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Ayar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.